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ABSTRACT
Objective To assess the efficacy of recombinant
human erythropoietin (rhEPO) in amyotrophic lateral
sclerosis (ALS).
Methods Patients with probable laboratory-supported,
probable or definite ALS were enrolled by 25 Italian
centres and randomly assigned (1:1) to receive
intravenous rhEPO 40 000 IU or placebo fortnightly as
add-on treatment to riluzole 100 mg daily for
12 months. The primary composite outcome was
survival, tracheotomy or >23 h non-invasive ventilation
(NIV). Secondary outcomes were ALSFRS-R, slow vital
capacity (sVC) and quality of life (ALSAQ-40) decline.
Tolerability was evaluated analysing adverse events (AEs)
causing withdrawal. The randomisation sequence was
computer-generated by blocks, stratified by centre,
disease severity (ALSFRS-R cut-off score of 33) and onset
(spinal or bulbar). The main outcome analysis was
performed in all randomised patients and by intention-
to-treat for the entire population and patients stratified
by severity and onset. The study is registered, EudraCT
2009-016066-91.
Results We randomly assigned 208 patients, of whom 5
(1 rhEPO and 4 placebo) withdrew consent and 3
(placebo) became ineligible (retinal thrombosis,
respiratory insufficiency, SOD1 mutation) before receiving
treatment; 103 receiving rhEPO and 97 placebo were
eligible for analysis. At 12 months, the annualised rate of
death (rhEPO 0.11, 95% CI 0.06 to 0.20; placebo: 0.08,
CI 0.04 to 0.17), tracheotomy or >23 h NIV (rhEPO 0.16,
CI 0.10 to 0.27; placebo 0.18, CI 0.11 to 0.30) did not
differ between groups, also after stratification by onset
and ALSFRS-R at baseline. Withdrawal due to AE was
16.5% in rhEPO and 8.3% in placebo. No differences
were found for secondary outcomes.
Conclusions RhEPO 40 000 IU fortnightly did not
change the course of ALS.
INTRODUCTION
Several in vitro and in vivo models of degenerative,
toxic and inflammatory peripheral and central
nervous system diseases have shown that
erythropoietin (EPO) and its non-erythropoietic
derivatives have neuroprotective properties.1 EPO
is a circulating glycoprotein whose principal func-
tion is the production of red blood cells through the
inhibition of erythroid progenitor apoptosis and
regulation of differentiation in the bone marrow.
Endogenous EPO and the recombinant human EPO
(rhEPO) form are identical regarding the sequence
of amino acids, but have heterogeneous bioavailabil-
ity and pharmacokinetics due to the different com-
position of the sugar side chains, indicated by a
Greek letter suffix (eg, α, β, γ and δ). EPO and its
classical receptor (EPOR) are expressed in human
neurons and astrocytes. Preclinical studies demon-
strating that non-erythropoietic EPO derivatives
could also be tissue protective2 suggested the exist-
ence of a further non-haematopoietic receptor
(EPOR)2, shared by members of the interleukin-3
receptor family.3 Nevertheless, studies in rodent
models demonstrated that the expression of the clas-
sical EPOR was mandatory for EPO-induced
neuroprotection.4
The hypothesis that EPO could specifically exert
a protective effect on motor neurons arose from
several lines of research. EPO was found to protect
cultured motor neurons from serum-BDNF (brain-
derived neurotrophic factor) deprivation or long-
term kainate exposure.5 Treatment with EPO and
non-erythropoietic derivatives improved motor per-
formances and protected from motor neuron
degeneration in the wobbler mouse model,
although the effects were limited to women and
survival was not prolonged.6 In SOD1G93A mice,
increased EPO and EPOR expression in the brain
cortex was interpreted as a possible compensatory
effect of altered neuronal function.7 In the same
model, EPO treatment delayed the onset of motor
deterioration and protected thoracic spinal cord
motor neurons from degeneration.8 However, this
effect could not be replicated.9 EPO was also found
to reduce SOD1 aggregates in motor neurons.10 In
patients with amyotrophic lateral sclerosis (ALS),
the cerebrospinal fluid EPO level was lower than in
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patients with other neurodegenerative diseases, and its concen-
tration was suggested to correlate with the progression of the
disease.11 Moreover, the cerebrospinal fluid concentration of
EPO and vascular endothelial growth factor were found to be
significantly higher and lower, respectively, in hypoxaemic
patients with ALS, suggesting an intact common oxygen-sensor
pathway.12 On the basis of the results of our previous pilot
study,13 we designed a double-blind, randomised, placebo con-
trolled trial to assess the efficacy of rhEPO as an add-on treat-
ment in patients with sporadic ALS.
METHODS
Patients
The trial was coordinated by the ALS Centre at the IRCCS
Foundation ‘Carlo Besta’ of Milan. Consecutive patients were
screened for eligibility at all the 25 Italian ALS centres. Patients
aged 18–75 years and diagnosed with probable laboratory-
supported, probable or definite ALS according to El Escorial
revised criteria were eligible. Inclusion criteria were onset of
weakness ≤18 months and slow vital capacity (sVC) ≥70% of
predicted in seated position at screening visit. Exclusion criteria
were haematocrit >51% in men and >49% in women, haemo-
globin value >17 g/dL; non-invasive ventilation (NIV) >6 h
daily; known familial ALS or first-degree relative with ALS;
diagnosis of frontotemporal dementia; history and/or instru-
mental evidence of previous thrombotic vascular event or
cardiac diseases; uncontrolled hypertension (systolic
≥160 mm Hg and diastolic ≥95 mm Hg irrespective of treat-
ments at two consecutive evaluations); active solid or myelopro-
liferative malignancy; known hypercoagulable disorders. All
patients were asked to continue riluzole 100 mg daily or to be
on a stable dose for at least 30 days prior to screening. Patients
who did not take riluzole at the screening visit were considered
eligible and could be randomized; in this case, they could not
start riluzole during the entire study period. The protocol was
approved by the ethics committee at each site. All patients pro-
vided written informed consent before any study-related
procedure.
Trial outcomes
The primary outcome was one single composite outcome of
time from randomisation to death, tracheotomy or >23 h NIV
daily for 14 consecutive days. Secondary outcomes were
changed from baseline in the ALSFRS-R score, sVC in the
seated position and patients’ quality of life measured by the
ALSAQ-40 questionnaire. Tolerability was evaluated analysing
adverse events (AEs) causing withdrawal.
Randomisation
Patients were randomly assigned to receive either intravenous
rhEPO 40 000 IU or matching placebo (1:1 ratio) fortnightly
for 12 months. Randomisation was stratified by centre, disease
severity (ALSFRS-R ≤33 vs >33) and onset (spinal or bulbar),
with a block size of four within each centre. The
Neuroepidemiology Unit at the coordinating centre, independ-
ent of the study, generated the computer-based randomisation
sequence known only to two staff persons and the drug dispen-
ser. Treatment was allocated by a web-based randomisation
system, available 24 h a day. The procedure incorporated eligi-
bility checks according to protocol and was performed on
request from the centres. The sequence was always available for
emergency unmasking.
Masking
RhEPO (Eprex) was purchased from Janssen-Cilag SpA
(Cologno Monzese, Italy) by the coordinating centre and dir-
ectly shipped to the company (Pierrel Research IMP srl, Cantù,
Italy) in charge of preparing the investigational drug (rhEPO or
1 cc of saline) in syringes of identical appearance, sealed in
sequentially numbered identical containers according to the
allocation sequence. Shipping was performed for each patient
within 1 week after randomisation using a refrigerated express
carrier. Each centre stored the investigational drug at −4°C.
Patients, neurologists, laboratory biologists/technicians (two at
each centre) and a statistician were masked to treatment alloca-
tion and did not have access to any data related to rhEPO haem-
atopoietic activity. Briefly, all participating centres generated a
specific access code for the blood withdrawals of patients with
ALS enrolled in the EPOS trial. At each treatment visit, the local
laboratory unit received the de-identified vial reporting the ran-
domisation number before treatment administration. Blood
parameters were emailed to the coordinating unit where a
trained person readily alerted the treating neurologist on the
decision to administer or delay the treatment based on safety
protocol parameters (see below). Patients and treating neurolo-
gists did not have access to any data on blood parameters,
whereas laboratory personnel did not have access to any data
allowing the identification of the patient. This procedure was
elaborated to maintain the blindness of the study. Finally, when
we designed the study, we reasoned that patients treated with
rhEPO could have had a higher risk of treatment delay as
defined by the safety protocol. Therefore, the randomisation
centre generated a list of placebo patients randomly assigned to
1 week treatment delay balanced with the number of patients
allocated on rhEPO treatment needing true delay at each centre.
This procedure was elaborated to maintain the blindness of the
study.
Procedures
After giving informed written consent, eligible patients under-
went haematological examinations (haemochromocytometry,
renal and liver function, serum iron, ferritin, transferrin, reticu-
locyte count, coagulation tests), blood pressure and body mass
index (BMI) measurement and sVC, ALSFR-R and ALSQ40
assessment. Randomisation was performed within 15 days after
the screening visit. At each fortnightly treatment visit, safety
parameters (haematocrit >51% in men and >49% in women
or haemoglobin value >17 g/dL and value raised >1 g/dL at the
end of the interval between two subsequent doses), blood pres-
sure and BMI were assessed. Symptoms of nocturnal hypoventi-
lation (nocturnal arousals, morning headache, excessive daytime
sleepiness, vivid dreams), medications and AE were actively
monitored and recorded. ALSFR-R and sVC were assessed
monthly. At the 6-month and study end or dropout visit, the
patient also underwent complete haematological examinations
and ALSAQ-40 assessment. At each treatment visit, treatment
administration was allowed or delayed for 1 week by the trial
coordinating office after assessment of safety parameters. If
treatment was delayed, the following week safety parameters
were repeated before drug administration. The delay of treat-
ment administration for more than two times caused the
dropout of the patient. After the study end at month 12,
patients underwent monthly follow-up visits for a further
6 months to record primary outcome events. All centres were
provided with a spirometer (Spirobank G multifunction,
Medisan srl, Milano, Italy) and disposable tubes for sVC
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assessment, and trained in its use. All data were recorded by an
electronic case record form specifically developed (Nubilaria srl,
Novara, Italy). Trial monitoring was performed by an independ-
ent contract research organisation (CROM srl, Verona, Italy)
that assured consistency in measuring outcomes across centres
by scheduled site visits.
Co-treatments
Nutritional status and ventilation could affect survival and thus
the primary outcome of the trial. During the first investigator
meeting held in Milan on 6 June 2010, all participating centres
agreed on the approach to cotreatments, sharing the opinion
that the ultimate decision would be personal to each patient. We
agreed that percutaneous endoscopic gastrostomy or an equiva-
lent device should be proposed to all patients in the case of
score 1 or 2 at item 3 of the ALSFRS-R, unintentional loss of
body weight >10% in the past 3 months or choking during
food, liquids or medication ingestion. NIV should be proposed
to all patients in the case of score 0 or 1 at item 10 or 11 of the
ALSFRS-R, sVC<50% or abnormal nocturnal oximetry (SaO2
<90% for 4% of the overnight recorded time).
Sample size estimation
On the basis of the results of our pilot study (ie, observed rates
of 0.56 for death and 0.33 for tracheotomy at 18 months in the
placebo group),13 we estimated that we would need a sample
size of 203 patients followed up for 12 months to give 97%
power to detect a significant difference between rhEPO and
placebo corresponding to a 67% relative reduction of risk of
death and 74% power to detect a 70% relative reduction of risk
of respiratory events (tracheotomy or >23 h NIV), with a two-
sided type 1 error of 5% and given an anticipated dropout rate
of 10%.
Statistical analysis
The main analysis of primary and secondary outcomes included
all randomised patients who took at least one dose of the investi-
gational drug in their original assigned groups. All analyses were
performed both for the entire population and for the subgroups
of patients with ALSFRS-R ≥33 or <3314 and with spinal or
bulbar onset at randomisation. A per-protocol analysis was
carried out excluding non-compliers (patients who took <80%
therapy). Demographic characteristics and clinical features of
randomised patients at baseline were reported by treatment arm
and compared using χ2 test, student t test, Wilcoxon rank-sum
test or Fisher’s exact test as appropriate. Time from randomisa-
tion to death, tracheotomy or >23 h NIV daily for 14 consecu-
tive days was analysed in terms of the annualised rate with the
corresponding 95% CI, and p value using a χ2 test with one
degree of freedom for rate comparison (based on Poisson regres-
sion). The Kaplan-Meier method was used to obtain survival
curves with the corresponding log-rank test. A Cox model was
applied to estimate the treatment effect in terms of HR with 95%
CI, adjusted for sex, age, ALSFRS-R score at baseline and disease
duration. The number of patients experiencing an AE causing
withdrawal were reported and compared between the two
groups by Kaplan-Meier curves of the time to withdrawal and
the corresponding log-rank test. Change from baseline in sVC,
Figure 1 Flow chart of the EPOS trial. CONSORT flow diagram. Flow diagram showing the progress of patients throughout the EPOS trial. ALS,
amyotrophic lateral sclerosis rhEPO; recombinant human erythropoietin.
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ALSFRS-R and ALSAQ-40 was assayed by mixed effect models.
All data were analysed using SAS V.9.3 (SAS Institute INC. Cary,
North Carolina, USA). This study is registered with EudraCT,
number 2009-016066-91 (EPOS trial).
RESULTS
Between August 2010 and November 2012, 208 of 545 eligible
patients (38%) were randomly allocated to the treatment arms
(104 in the rhEPO arm and 104 in the placebo arm; figure 1).
Patients were recruited at 25 Italian ALS centres from 13 regions
(figure 2). Table 1 shows the demographic and clinical character-
istics of the treatment groups at baseline. In the analysis of the
primary outcome performed on all patients who received at least
one dose of the interventional treatment (eg, 103 patients in the
rhEPO arm and 97 patients in the placebo arm), the rate of
events (death, tracheotomy, >23 h NIV) at 12-month follow-up
did not differ between the treatment groups, even after stratifica-
tion by disease severity and onset (table 2). The Kaplan-Meier
analysis did not disclose any difference in terms of the log-rank
test (p=0.99; figure 3) and Peto test (p=0.89). The correspond-
ing HR between rhEPO and placebo, adjusted for gender, age,
ALSFRS-R score and disease duration, was 1.02 (95% CI 0.57 to
1.83). The analysis of efficacy by intention-to-treat performed on
all randomised patients (eg, 104 patients in the rhEPO and
placebo groups) yielded the same results.
The percentage of AE causing withdrawal was twice as high
in the rhEPO (16.5%) group as in the placebo (8.3%) group,
although the difference was not significant in terms of the
log-rank test (p=0.16), most likely due to the small number of
events (table 3; figure 4). In the rhEPO group, we recorded four
cases of deep venous thrombosis complicated in two cases by
pulmonary embolism, two cases of cardiac arrhythmia, four
cases of treatment suspension for >8 weeks and seven cases of
delay more than two times due to altered safety parameters. In
the placebo group, we recorded one case of deep venous throm-
bosis, one case of cardiac infarction, four cases of treatment sus-
pension for >8 weeks and two cases of delay more than two
times due to altered safety parameters (table 3).
The analysis of the secondary outcomes during the
12 months of follow-up did not show differences between
groups either in ALSFRS-R (p of mixed-effects models=0.31)
and sVC (p of mixed-effects models=0.47) decline (figure 5) or
ALSAQ-40 score (+29 points in the rhEPO group and +37
points in the placebo group from baseline to 12 months; p of
mixed-effects models=0.23).
All the above analyses were also performed for the subgroups
of patients with ALSFRS-R ≥33 or <33 at randomisation and
with spinal or bulbar onset, and per-protocol, and did not show
any significant difference between the two treatment groups
(data not shown). Haemoglobin and haematocrit values over-
lapped in the rhEPO and placebo groups at baseline, whereas
they were significantly (p<0.01) higher in the rhEPO group
than the placebo group throughout the entire study period
(figure 6).
Figure 2 Italian centres participating in the EPOS trial with a number of patients enrolled in brackets.
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At 18-month follow-up, 6 months after the treatment was
stopped, 41 (41%; 3 lost to follow-up) of 100 patients in the
rhEPO group and 31 (33.3%; 4 lost to follow-up) of 93 placebo
patients reached the primary outcome (death or tracheotomy).
DISCUSSION
Several studies suggested that EPO can promote the homeostasis
of cells under stress and exert protective actions on different
tissues. Peripheral administration allows EPO to penetrate
through an intact blood-brain-barrier,15–17 and this has been
exploited to test its neurotrophic effects in multiple sclerosis,
Parkinson’s disease and schizophrenia.18 19 Encouraging preclin-
ical studies with EPO and its non-erythropoietic derivatives in
models of central and peripheral nervous system degenerative
diseases,2 expression of the non-erythropoietic receptor
(EPOR)2 in motor neurons
6 and preliminary data from ALS
mouse models8 and a pilot clinical trial13 suggested that patients
with ALS might benefit from rhEPO treatment. Conversely, our
study demonstrated that rhEPO administered at the dose of
40 000 IU fortnightly did not change either survival or disability
at 12 months. Patients’ demographic and clinical features were
well balanced between the treatment arms, supporting the reli-
ability of the results. The significant and stable increase of
haemoglobin and haematocrit values in the rhEPO group
throughout the entire treatment period demonstrated that
rhEPO exerted its expected haematological effects, and there-
fore it was not degraded in patients with ALS. This observation
strengthens our negative findings, suggesting that the lack of
neuroprotective effect could not be attributed to an altered bio-
logical activity of rhEPO at the haematological level.
Our negative findings appear to be in keeping with those dis-
appointing from previous clinical studies investigating rhEPO
neuroprotection in critical illness and patients with stroke.1
RhEPO may remain a promising treatment in schizophrenia19
and in the prevention of cognitive impairment after cardiac
surgery and cardiopulmonary bypass,20 though these prelimin-
ary data need larger confirmatory studies. Therefore, despite the
bulk of preclinical findings in favour of a substantial protective
activity of EPO outside the bone marrow, no evidence is cur-
rently available to support the hypothesis that rhEPO can rescue
injured neurons in patients with acute or chronic progressive
neurological diseases like stroke and ALS.
In most previous clinical studies of neuroprotection, cardio-
protection and renal protection, rhEPO was acutely administered
at doses ranging from 40 000 IU daily for 3 days to 50 000 IU 24
and 48 h after the event, whereas in critically ill patients the
schedule was 40 000 IU weekly for 3 weeks.1 Ours is the first
trial in which rhEPO was chronically administered to non-
Table 1 Demographic characteristics and clinical features of
randomised patients at baseline in the two treatment groups
rhEPO (n=103) PLACEBO (n=97)
Gender
Men 55 (53.4%) 50 (51.6%)
Women 48 (46.6%) 47 (48.5%)
Age (years)
Mean (SD) 59.4 (9.7) 58.6 (10.5)
Median (range) 62 (25–73) 60 (25–75)
Onset
Bulbar 27 (26.2%) 25 (25.8%)
Spinal 76 (73.8%) 72 (74.2%)
Disease duration (years)
Mean (SD) 1.0 (0.4) 1.1 (0.3)
Median (range) 1.0 (0.3–1.7) 1.1 (0.2–1.6)
ALSFRS-R
Mean (SD) 38.4 (5.8) 38.3 (5.8)
Median (range) 40 (21–48) 39 (20–48)
sVC
Mean (SD) 86.7 (14.5) 86.2 (16.0)
Median (range) 87 (37–110) 86 (23–114)
ALSAQ40
Mean (SD) 100 (30) 99 (24)
Median (range) 98 (43–200) 97 (52–161)
Riluzole treatment
Yes 100 (97.1%) 92 (94.9%)
Svc, slow vital capacity; rhEPO, recombinant human erythropoietin.
Table 2 Analysis of efficacy for the primary outcome at 12-month follow-up
rhEPO (n=103; PY=92) Placebo (n=97; PY=88) p Value
Overall events (death, tracheotomy, >23 h NIV)
N (annualised rate; 95% CI) 25 (0.27; 0.18 to 0.40) 23 (0.26; 0.17 to 0.39) 0.88
Death
N (annualised rate; 95% CI) 10 (0.11; 0.06 to 0.20) 7 (0.08; 0.04 to 0.17) 0.52
Tracheotomy or >23 h NIV
N (annualised rate; 95% CI) 15 (0.16; 0.10 to 0.27) 16 (0.18; 0.11 to 0.30) 0.77
Overall events stratified by disease onset and severity
Spinal onset n=76; PY=68 n=72; PY=65 0.73
N (annualised rate; 95% CI) 21 (0.31; 0.20 to 0.47) 18 (0.28; 0.17 to 0.44)
Bulbar onset n=27; PY=24 n=25; PY=23 0.71
N (annualised rate; 95% CI) 4 (0.17; 0.06 to 0.45) 5 (0.22; 0.09 to 0.52)
ALSFRS-R ≥33 n=86; PY=79 n=84; PY=77 0.69
N (annualised rate; 95% CI) 17 (0.22;0.13 to 0.35) 19 (0.25; 0.16 to 0.39)
ALSFRS-R <33 n=17; PY=13 n=13; PY=12 0.37
N (annualised rate; 95% CI) 8 (0.60; 0.30 to 1.20) 4 (0.35; 0.13 to 0.93)
The analysis was performed in terms of the annualised rate with the corresponding 95% CI and p value using a χ2 test with one degree of freedom for rate comparison (based on
Poisson regression).
NIV, non-invasive ventilation; PY, total patient-years of follow-up; rhEPO, recombinant human erythropoietin.
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anaemic patients with a degenerative disease for a 12-month
period. One limitation may appear to be the lack of a previous
dose-finding study. However, we have chosen the dosing schedule
of rhEPO 40 000 IU fortnightly based on the pharmacokinetic
profile, the known linear relationship between a single dose
administered and erythropoietic response, and the turnover of
reticulocytes,21 with the aim of reducing the thrombotic risk in
patients. Moreover, acute higher doses used in previous clinical
studies increased the rate of thrombotic vascular events.1
40 000 IU approximately equals one-third of the maximally
effective single dose in a 70 kg participant (eg, 1800 IU/kg). In
our study, it did not significantly increase the rate of thrombotic
complications compared with the placebo group, most likely due
to the small number of events, being the overall number of AEs
twice as high as in the rhEPO treated group. In rodent models,22
the dose of 2500 IU/kg/day was reported to be the most effective
for neuroprotection but caused an increase of haematocrit value
that would not be acceptable in humans.
Figure 3 Primary outcome analysis.
Survival probability in terms of death,
tracheotomy and 23 h non-invasive
ventilation for 14 consecutive days
during the 12 months of the EPOS
trial, with the corresponding p value of
the log-rank test.
Table 3 Number and percentage of AEs causing withdrawal in
the two treatment groups
rhEPO
(N=103)
PLACEBO
(N=97)
Total
(N=200)
Serious AEs
N (%) 17 (16.5) 8 (8.3) 25 (12.5)
Causes
Treatment suspended >8 weeks 4 4 8
Altered safety examinations 7 2 9
Myocardial infarction 0 1 1
Pulmonary embolism 2* 0 2*
Deep venous thrombosis 4 1 5
Cardiac arrhythmia 2 0 2
*Secondary to deep venous thrombosis.
AEs, adverse events; rhEPO, recombinant human erythropoietin.
Figure 4 Adverse event analysis.
Survival probability in terms of adverse
events causing withdrawal during the
12 months of the EPOS trial, with the
corresponding p value of the log-rank
test.
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A recent reappraisal of patients’ clinical features included in ALS
trials suggested that the intrinsic limitations imposed by a classical
randomised clinical trial can lead to the exclusion of patients
representing the ALS population in clinical practice, reducing the
reliability of the results.23 It has been suggested that the enrolment
of patients in the earliest phases of ALS could increase the prob-
ability of identifying successful disease-modifying treatments. In
our study, the percentage of patients excluded due to respiratory
insufficiency (15%) and of those who did not reach the diagnostic
certainty level of probable ALS according to the revised El Escorial
criteria (1.5%) at randomisation was small compared with previ-
ous trials. Similarly, gender distribution was well balanced between
arms, thus avoiding the underrepresentation of women observed
in other trials.23 However, the mean age of ALS onset was slightly
lower than that recorded in epidemiological studies,24–27 possibly
accounting for the lower 1-year death rates.
Like previous trials in ALS, results from our pilot study did
not replicate in the larger phase III trial. In particular, in the
pilot study, we had observed a higher prevalence of primary
outcome events (death and tracheotomy) in the placebo group
at 18 months follow-up, most likely a chance result due to the
small sample size. In ALS, the most important goal of new treat-
ments which can protect motor neurons and axons from pro-
gressive degeneration in a time frame that is useful to patients
remains far from be achievement. Our phase III randomised
trial demonstrated that rhEPO does not have any positive effect
on the course of ALS, lengthening the list of disappointing
results from all the previous studies.28–37
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